In LiSyM-Cancer, 51 partners working on 37 subprojects at 23 academic institutions distributed over 15 cities with altogether app. 130 multidisciplinary staff cooperate to investigate the development of liver cancer from pre-existing conditions such as non-alcoholic fatty liver disease (NAFLD) or cirrhosis of the liver aiming at the identification of relevant biomarkers for the early diagnosis and prevention of early liver cancer (Hepatocellular Carcinoma (HCC)).
Our network is accompanied by an international Scientific Advisory Board (SAB) consisting of renowned experts in the research area of LiSyM-Cancer.
The Project Management Jülich (PtJ) works on behalf of the Federal Ministry of Education and Research (BMBF) to administer and implement the funding programme and is the interface between LiSyM-Cancer and the BMBF.
LiSyM-Cancer has a project duration of three years, running from July 2021 to July 2024.